1. Home
  2. CRVS vs OPP Comparison

CRVS vs OPP Comparison

Compare CRVS & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRVS
  • OPP
  • Stock Information
  • Founded
  • CRVS 2014
  • OPP 2010
  • Country
  • CRVS United States
  • OPP United States
  • Employees
  • CRVS N/A
  • OPP N/A
  • Industry
  • CRVS Biotechnology: Pharmaceutical Preparations
  • OPP Finance/Investors Services
  • Sector
  • CRVS Health Care
  • OPP Finance
  • Exchange
  • CRVS Nasdaq
  • OPP Nasdaq
  • Market Cap
  • CRVS 206.5M
  • OPP 204.1M
  • IPO Year
  • CRVS 2016
  • OPP N/A
  • Fundamental
  • Price
  • CRVS $3.63
  • OPP $8.19
  • Analyst Decision
  • CRVS Strong Buy
  • OPP
  • Analyst Count
  • CRVS 3
  • OPP 0
  • Target Price
  • CRVS $15.67
  • OPP N/A
  • AVG Volume (30 Days)
  • CRVS 906.6K
  • OPP 108.0K
  • Earning Date
  • CRVS 05-05-2025
  • OPP 01-01-0001
  • Dividend Yield
  • CRVS N/A
  • OPP 14.41%
  • EPS Growth
  • CRVS N/A
  • OPP N/A
  • EPS
  • CRVS N/A
  • OPP N/A
  • Revenue
  • CRVS N/A
  • OPP N/A
  • Revenue This Year
  • CRVS N/A
  • OPP N/A
  • Revenue Next Year
  • CRVS N/A
  • OPP N/A
  • P/E Ratio
  • CRVS N/A
  • OPP N/A
  • Revenue Growth
  • CRVS N/A
  • OPP N/A
  • 52 Week Low
  • CRVS $1.43
  • OPP $7.26
  • 52 Week High
  • CRVS $10.00
  • OPP $8.83
  • Technical
  • Relative Strength Index (RSI)
  • CRVS 55.04
  • OPP 42.55
  • Support Level
  • CRVS $3.15
  • OPP $7.99
  • Resistance Level
  • CRVS $3.78
  • OPP $8.25
  • Average True Range (ATR)
  • CRVS 0.25
  • OPP 0.21
  • MACD
  • CRVS 0.12
  • OPP 0.01
  • Stochastic Oscillator
  • CRVS 87.90
  • OPP 56.72

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.

Share on Social Networks: